The amyloid debate plays out at BIO
Speaking of Alzheimer’s drug development, you may not be surprised to learn that Biogen isn’t alone in seeing remaining glimmers of hope when it comes to the amyloid hypothesis.
Speaking on an Alzheimer’s session at this week’s virtual BIO convention, Susan Catalano, the co-founder and CSO of Cognition Therapeutics, said her company is still indirectly targeting it for drug development, in part because she thinks other researchers didn’t appreciate the different forms the plaque-forming substance can take.
Others on the panel, STAT’s Kate Sheridan reports, suggested it was time to move on. Michal Preminger, the head of Johnson & Johnson Innovation’s eastern North American division, told viewers: “We see the industry recognizing — with some humility — the need to look back at the fundamentals.”
Read more.
Speaking on an Alzheimer’s session at this week’s virtual BIO convention, Susan Catalano, the co-founder and CSO of Cognition Therapeutics, said her company is still indirectly targeting it for drug development, in part because she thinks other researchers didn’t appreciate the different forms the plaque-forming substance can take.
Others on the panel, STAT’s Kate Sheridan reports, suggested it was time to move on. Michal Preminger, the head of Johnson & Johnson Innovation’s eastern North American division, told viewers: “We see the industry recognizing — with some humility — the need to look back at the fundamentals.”
Read more.
.png)
No hay comentarios:
Publicar un comentario